Global Diabetic Nephropathy Market, By By Drug Class (Diuretics, Antioxidant Inflammation Modulator, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Renin Inhibitors, Calcium Channel Blockers, Others), Type (Type-1 Diabetes and Type-2 Diabetes), Route of Administration (Oral, Parental, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Diabetic Nephropathy Market Analysis and Size
The global diabetic nephropathy market is expected to witness significant growth during the forecast period. The factors primarily driven the growth of global diabetic nephropathy market are high prevalence of diabetes as diabetic nephropathy is a very common indication and presence of diabetic management centres. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global diabetic nephropathy market in the forecast period 2022-2029. The expected CAGR of global diabetic nephropathy market is tend to be around 6.3% in the mentioned forecast period. The market was valued at USD 3114.38 million in 2021, and it would grow upto USD 4779.60 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Diabetic nephropathy is also termed as diabetic kidney disease characterized by development of hypertension and hyperglycaemia which induces the changes in the multiple pathways that contribute to morphological changes in the kidneys and eventually leads to the kidney damage. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Global Diabetic Nephropathy Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Drug Class (Diuretics, Antioxidant Inflammation Modulator, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Renin Inhibitors, Calcium Channel Blockers, Others), Type (Type-1 Diabetes and Type-2 Diabetes), Route of Administration (Oral, Parental, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Bristol Myers Squibb Company (U.S.) GlaxoSmithKline Plc. (U.S.), Bayer AG (Germany) |
|
Market Opportunities |
|
Global Diabetic Nephropathy Market Dynamics
Drivers
- Rising Awareness For Disease Treatment
Rising awareness among patients and healthcare professionals for the treatment of diabetes and more and more usage of combination therapy are the driving factors that is expected to boost the demand for global diabetic nephropathy market during the forecast period of 2022-2029.
- Increased Clinical Studies and Government Initiatives
The global diabetic nephropathy market is estimated to be driven by the rising R&D investments in drug discovery and development and the rising prevalence of diabetes. For instance, as per the reports of International Diabetes Federation, around 415 million people are currently affected by diabetes globally and it is hoped to increase to 642 million diabetic people by the year 2040.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increasing Demand for angiotensin-converting enzyme inhibitors
The angiotensin-converting enzyme inhibitors are widely used due to increase in number of temporary as well as permanent chronic heart disease, hypertension heart attack, and diabetic nephropathy. Thus, it boosts the market growth.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global diabetic nephropathy market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global diabetic nephropathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global diabetic nephropathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Diabetic Nephropathy Market
The Covid-19 pandemic let a negative impact on the global diabetic nephropathy market because the utmost priority was given to Covid-19 patients for treatment. Several medical colleges and hospitals were reorganised and helped in the structure so that they can accommodate more patients diagnosed with Covid-19. Discovery and development of diabetic nephropathy drugs also slowed down during the pandemic, but surely it wasn’t in a pause and now in the post pandemic era, it is rising again.
Global Diabetic Nephropathy Market Scope
The global diabetic nephropathy market is segmented on the basis of drug class, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Diuretics
- Antioxidant Inflammation Modulator
- Angiotensin Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
- Renin Inhibitors
- Calcium Channel Blockers
- Others
Type
- Type-1 Diabetes
- Type-2 Diabetes
Route of Administration
- Oral
- Parental
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Diabetic Nephropathy Market Regional Analysis/Insights
The global diabetic nephropathy market is analysed and market size insights and trends are provided by type, drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global diabetic nephropathy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increasing infection in geriatric population, and growing population with cardiovascular diseases.
Asia-Pacific dominates the market due to increased prevalence of lung infections and associated diseases and increasing initiatives taken by the government and pharmaceutical organizations to spread awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Diabetic Nephropathy Market Share Analysis
The global diabetic nephropathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global diabetic nephropathy market.
Key players operating in the global diabetic nephropathy market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bristol Myers Squibb Company (U.S.)
- GlaxoSmithKline Plc. (U.S.)
- Bayer AG (Germany)
SKU-
